Loading
A phase 1/2 trial of Balstilimab in colorectal cancer and gastric & gastro-oesophageal junction cancer, run by Rottapharm Biotech, active and no longer recruiting.
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is a phase 1/2 interventional study registered as NCT05205330 by Rottapharm Biotech, with 107 participants enrolled, started 2021-11-23 and due to reach its primary completion in 2026-12. Interventions recorded: CR6086 and AGEN2034.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Agenus, Balstilimab and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Balstilimab and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/